# Difference between revisions of "Chance News 70"

## Quotations

"The interpretation of statistical signiﬁcance tests is liable to a misconception known as the fallacy of the transposed conditional. In this fallacy, the probability of the data given a hypothesis (e.g., P(D|H), such as the probability of someone being dead given that they were lynched, a probability that is close to 1) is confused with the probability of the hypothesis given the data (e.g., P(H|D), such as the probability that someone was lynched given that they are dead, a probability that is close to zero)."

Eric–Jan Wagenmakers, et.al., writing in
Why psychologists must change the way they analyze their data: The case of Psi

The authors are criticizing naive use of p-value in the recent ESP research controversy.

Submitted by Paul Alper

”If you averaged the highs and lows of a rollercoaster, it wouldn’t be much of a thrill ride; same with the threat of flu.”

Rebecca Goldin in “The flu: It’s about variance”
STATS, September 3, 2010

The author reports that CDC flu-death counts have ranged from 3,300 to almost 50,000 in various years, making the yearly average unreliable as an exclusive basis of public health decisions.

Submitted by Margaret Cibes

## Forsooth

From a novel, The Kills, by Linda Fairstein, Scribner, 2004:

“Hey, how many people do you need to have in a room to guarantee the chance that at least two of them would have the same birthday?”

“I don’t know. Three hundred sixty-four.”

“Hah! Twenty-three. At least two out of every twenty-three people will have exactly the same birthday. Statistical odds. A lot of life is coincidence.”

Submitted by Margaret Cibes

## New ESP study raises ruckus

Read about a new study in which a Cornell psychologist claims to have verified "ESP":
“ESP Study Gets Published in Scientific Journal, by Ned Potter, ABC World News, January 6, 2011 (including 2-min video interview).
“Journal’s paper on ESP Expected to Prompt Outrage”, by Benedict Carey, The New York Times, January 5, 2011.

“Feeling the Future: Experimental Evidence for Anomalous Retroactive Influences on Cognition and Affect”, by Daryl J. Bem, Cornell University, Journal of Personality and Social Psychology, 2010.

“Why Psychologists Must Change the Way They Analyze Their Data”, by Eric-Jan Wagenmakers et al., University of Amsterdam.

We reanalyze Bem’s data using a default Bayesian t-test and show that the evidence for psi ["ESP"] is weak to nonexistent. …. We conclude that Bem’s p-values do not indicate evidence in favor of precognition; instead, they indicate that experimental psychologists need to change the way they conduct their experiments and analyze their data.

Submitted by Margaret Cibes based on an ISOSTAT posting by Randall Pruim

For more discussion, see Andrew Gelman's blog post (1/6/11) That silly ESP paper and some silliness in a rebuttal as well, and reader comments there.

## Placebos without deception

Patients in study who knew they were taking placebo still felt better
by Deborah Kotz, Boston Globe, 23 December 2010

Although somewhat of an exaggeration, before the invention of aspirin, MDs had nothing to offer except placebos. Today, no study in the medical field can be taken seriously without a control for the so-called placebo effect. In an unusual twist whereby the placebo is the treatment, Kaptchuk, et al openly beforehand informed 37 patients suffering from irritable bowl syndrome (IBS) that they were receiving a placebo “without any medication in it.” The other 43 patients were a control, i.e., no treatment, in that they received no medication whatsoever.

The Globe article put it this way:

The researchers got some astounding results when they gave placebos — gelatin capsules filled with nondigestible cellulose — to patients suffering from irritable bowel syndrome for three weeks. Nearly 60 percent reported an improvement in their symptoms compared with 35 percent of the patients who took nothing beyond their usual treatments. But here is the kicker: The placebo takers knew they were popping the equivalent of sugar pills, yet they still said they experienced less abdominal pain, constipation, or loose stools during the study.

Discussion

1. Here is the table of treatment outcomes from the Kaptchuk paper and an associated graphic (the phrase “Open Placebo” means no deception). Use a statistics package to verify the p-values given there.

2. Just to confuse things now that the power of the placebo has been firmly established for IBS, consider this which also was recently published:

In two studies involving more than 1,200 subjects with diarrhea-predominant IBS, researchers found that a two-week course of the antibiotic rifaximin helped relieve symptoms not only during treatment, but also for weeks after the medication was stopped.

Participants who were randomly assigned to receive the drug reported less bloating and abdominal pain, and improved stool consistency for up to 10 weeks, say the authors, whose paper is published in this week's New England Journal of Medicine.

About 40 per cent or more of subjects given the thrice-daily rifaximin pill had significantly diminished IBS symptoms compared to those given placebo, or dummy pills, the study found.

Dr. Lawrence Cohen who was not involved with the study

said rifaximin could have potential, although how much is difficult to determine because the difference in the proportion of those reporting symptom relief in the study's treated group versus the placebo group wasn't that dramatic.

"It's statistically significant, yes. But is it clinically significant?"

While the findings shouldn't be dismissed, Cohen said he is cautious about the study because it was designed and funded by rifaximin's maker, Salix Pharmaceuticals Inc., a fact disclosed by the researchers. Pimentel [director of the Gastrointestinal Motility Program at Cedars-Sinai Medical Center] discovered the use of rifaximin for IBS, and Cedars-Sinai holds patent rights to this discovery and has licensed those rights to Salix.

Submitted by Paul Alper

## Go figure, go finger

by Tim Dowling, Gaurdian, 1 December 2010

Times are hard and academics need to publish in an environment in which not a great deal of money is available for gathering data. A popular way to do things inexpensively and create a stir in the lay press is to look at finger lengths. Previous Chance News wikis on the subject of finger lengths may be found here and here.

In the present article, Tim Dowling comments on the more unusual past claims put forward in academic journals regarding finger length as destiny:

Did you know the length of your ring finger could indicate whether or not you are fertile, prone to prostate cancer or, if you are a women, likely to be a lesbian?

…men with longer ring fingers tended to be more fertile. It's the other way round for women.

…[financial] traders with longer ring fingers made more money than their short ring-fingered colleagues. They're also thought to be more aggressive, and more likely to take risks.

…lesbian women tended to have the more masculine (long ring, short index) finger arrangement.

…women with longer ring fingers did better [on spatial skills such as driving] than those whose ring fingers were equal to, or shorter than, their index fingers.

He sums up the previous results with this picture:

However, the latest connection with fingers seems to indicate that men whose ring fingers are longer than their index fingers are more likely to develop prostate cancer. Its conclusion is “Pattern of finger lengths may be a simple marker of prostate cancer risk, with length of 2D greater than 4D suggestive of lower risk.” However, from prostatecancerinfolink.net we learn that

the report in the British Journal of Cancer (2011) 104, 175–177. doi:10.1038/sj.bjc.6605986 is so hedged about with “mays” and “maybes” that it is unlikely to be considered definitive by too many people. We quote as follows (with bold italic type added for emphasis):

“The ratio of digit lengths is fixed in utero, and may be a proxy indicator for prenatal testosterone levels.”

“Compared with index finger shorter than ring finger …, men with index finger longer than ring finger … showed a negative association, suggesting a protective effect with a 33% risk reduction.”

“Pattern of finger lengths may be a simple marker of prostate cancer risk.”

Discussion

1. The Mermaid’s Tale points out a possible useful aspect of this study:

Of course, on the positive side, a glance at the hand is less embarrassing than a real DRE (digital rectal exam), or a PSA [prostate specific antigen] test to look for prostate cancer. It may be as useful, at least in terms of risk. It's a lot cheaper. Of course the PSA testing companies are likely to resist this current interpretation.

Determine the typical cost of a PSA test. The PSA test is a very common screening test in the United States and much less employed in other countries such as England. What does the following graph

suggest about the efficacy of screening? Although the five-year survival rates are not shown, what does the graph suggest about five-year survival rates in the various countries? What does it suggest about finger length?

2. The three-page British Journal of Cancer study relating prostate cancer and finger length cites 19 authors plus two institutions, The UK Genetic Prostate Cancer Study Collaborators and British Association of Urological Surgeons' Section of Oncology, whose “Lists [are] available on request.” There were 1524 subjects who had prostate cancer and 3044 subjects in the control arm. Information is given for the right hand only.

Table 2. Right-hand pattern and prostate cancer risk

Finger pattern Advanced cases (%) Controls (%) OR † 95% CI P-value
Index shorter than ring 872 (57.2) 1570 (51.6) 1.00
Index equal to ring 305 (20.0) 538 (17.7) 1.05 0.88–1.25 0.580
Index longer than ring 347 (22.8) 936 (30.8) 0.67 0.57–0.80 <0.001
Total 1524 (100.0) 3044 (100.0)

Abbreviations: CI=confidence interval; OR=odds ratio.
† Adjusted for age and social class.

Unlike previous studies of finger length, finger length in this study was self-reported. Why might this be an issue?

Submitted by Paul Alper